Clinical Trials
47 trialsTesting the SurVaxM Vaccine for Lung Cancer Prevention
National Cancer Institute (NCI)
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
National Cancer Institute (NCI)
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
National Institutes of Health Clinical Center (CC)
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
National Heart, Lung, and Blood Institute (NHLBI)
Vaccine Therapy in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
National Cancer Institute (NCI)
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
National Cancer Institute (NCI)
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
National Cancer Institute (NCI)
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
National Cancer Institute (NCI)
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
National Institutes of Health Clinical Center (CC)
Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
National Institutes of Health Clinical Center (CC)
p53 Vaccine for Ovarian Cancer
National Institutes of Health Clinical Center (CC)
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer
National Institutes of Health Clinical Center (CC)
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
National Cancer Institute (NCI)
Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
National Cancer Institute (NCI)
Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer
National Institutes of Health Clinical Center (CC)
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma
National Cancer Institute (NCI)
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
National Cancer Institute (NCI)
Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Biological Therapy in Treating Patients With Glioblastoma Multiforme
National Cancer Institute (NCI)
Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer
National Cancer Institute (NCI)
Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma
National Cancer Institute (NCI)
Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma
National Cancer Institute (NCI)
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
National Cancer Institute (NCI)
Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery
National Cancer Institute (NCI)
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
National Cancer Institute (NCI)
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
National Cancer Institute (NCI)
Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma
National Cancer Institute (NCI)
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)